Literature DB >> 15252744

Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy.

T Lawrenz1, H Kuhn.   

Abstract

Transcoronary alcohol ablation of septal hypertrophy (TASH) is a therapeutic catheter based option and an alternative to surgery in the treatment of patients with hypertrophic obstructive cardiomyopathy. However, the anatomic variability of the vascularisation of the obstructing septal bulge may limit the therapeutic efficacy. Thus, we examined an endocardial approach as an alternative. Based on the effects of radiofrequency energy in the treatment of cardiac arrhythmias this is the first report about the use of this modality. It refers to a 45-year-old patient with severe HOCM. The energy was applied by using a cooled-tip ablation catheter at the right side of the ventricular septum. The site corresponded to the obstructing area of the left ventricle. The following changes could be observed: a reduction of the intraventricular pressure gradient during the therapeutic session, a gradient reduction at cycle exercise as assessed by Doppler echocardiography 7 days after intervention, a subaortic septal hypokinesia, an enlargement of the left ventricular outflow tract, a reduction of the septal thickness and an increase in the exercise capacity using the 6-minute walk test. These changes are in accordance with the results after TASH and surgical treatment. The new modality might extend the possibilities in the catheter-based treatment of patients with severe HOCM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252744     DOI: 10.1007/s00392-004-0097-x

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  10 in total

1.  Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

Authors:  M Fassbach; B Schwartzkopff
Journal:  Z Kardiol       Date:  2005-05

2.  Radiofrequency catheter septal ablation for HOCM in childhood by M. Emmel, N. Sreeram, J. V. deGiovanni, K. Brockmeier; Z Kardiol 94:699-703 (2005).

Authors:  A A Schmaltz
Journal:  Clin Res Cardiol       Date:  2006-03       Impact factor: 5.460

3.  Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood.

Authors:  M Emmel; N Sreeram; J V deGiovanni; K Brockmeier
Journal:  Z Kardiol       Date:  2005-10

4.  Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in children.

Authors:  M Emmel; N Sreeram
Journal:  Neth Heart J       Date:  2005-12       Impact factor: 2.380

Review 5.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

6.  A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series.

Authors:  Lingqiu Kong; Yongchao Zhao; Hongwei Pan; Jianying Ma; Juying Qian; Junbo Ge
Journal:  Ann Transl Med       Date:  2021-06

Review 7.  Glue septal ablation: A promising alternative to alcohol septal ablation.

Authors:  Sercan Okutucu; Kudret Aytemir; Ali Oto
Journal:  JRSM Cardiovasc Dis       Date:  2016-03-03

8.  A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.

Authors:  Abhijeet B Shelke; Rajeev Menon; Anuj Kapadiya; Sachin Yalagudri; Daljeet Saggu; Sandeep Nair; C Narasimhan
Journal:  Indian Heart J       Date:  2016-04-14

9.  Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: A systematic review and meta-analysis.

Authors:  Haonan Yang; Yuan Yang; Yuzhou Xue; Suxin Luo
Journal:  Clin Cardiol       Date:  2020-02-07       Impact factor: 2.882

Review 10.  Role of endocardial septal ablation in the treatment of hypertrophic obstructive cardiomyopathy.

Authors:  Tolga Aksu; Tümer Erdem Güler; Kıvanç Yalın; Şükriye Ebru Gölcük; Kazım Serhan Özcan
Journal:  Anatol J Cardiol       Date:  2016-09       Impact factor: 1.596

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.